Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter by Qin, Jane Yuxia et al.
Systematic Comparison of Constitutive Promoters and
the Doxycycline-Inducible Promoter
Jane Yuxia Qin
1,2., Li Zhang
2., Kayla L. Clift
2, Imge Hulur
2, Andy Peng Xiang
3, Bing-Zhong Ren
1*,
Bruce T. Lahn
2*
1School of Life Sciences, Northeast Normal University, Changchun, China, 2Howard Hughes Medical Institute, Department of Human Genetics, University of Chicago,
Chicago, Illinois, United States of America, 3Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University, The Key Laboratory for Stem Cells and Tissue
Engineering, Ministry of Education, Guangzhou, China
Abstract
Constitutive promoters are used routinely to drive ectopic gene expression. Here, we carried out a systematic comparison of
eight commonly used constitutive promoters (SV40, CMV, UBC, EF1A, PGK and CAGG for mammalian systems, and COPIA and
ACT5C for Drosophila systems). We also included in the comparison the TRE promoter, which can be activated by the rtTA
transcriptional activator in a doxycycline-inducible manner. To make our findings representative, we conducted the comparison
in a varietyof cell types derived from severalspecies. We found that these promoters vary considerably from one another in their
strength.Mostpromotershavefairlyconsistentstrengthsacrossdifferentcell types,buttheCMVpromotercanvaryconsiderably
fromcelltypetocelltype.Atmaximalinduction,theTREpromoteriscomparabletoastrongconstitutivepromoter.Theseresults
should facilitate more rational choices of promoters in ectopic gene expression studies.
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Introduction
Many constitutive promoters are used to drive ectopic gene
expression in various in vitro and in vivo contexts. While a number
of studies have evaluated the strengths of these promoters in
various cellular contexts [1,2,3,4,5,6,7], there is generally a
shortage of systematic comparisons of the behaviors of commonly
used constitutive promoters across multiple cell types under the
same experimental conditions. The choice of which promoter to
use is therefore frequently based on technical convenience, such as
the availability of a promoter, rather than the suitability of the
promoter for a particular experiment. To facilitate more rational
choices of promoters in ectopic gene expression studies, we
decided to examine six constitutive promoters commonly used in
mammalian systems, including the simian virus 40 early promoter
(SV40), cytomegalovirus immediate-early promoter (CMV), hu-
man Ubiquitin C promoter (UBC), human elongation factor 1a
promoter (EF1A), mouse phosphoglycerate kinase 1 promoter
(PGK), and chicken b-Actin promoter coupled with CMV early
enhancer (CAGG). We also chose to examine two promoters
commonly used in Drosophila systems, including copia transposon
promoter (COPIA) and actin 5C promoter (ACT5C). Finally, we
included in the comparison the doxycycline-inducible system with
reverse tetracycline-controlled transactivator (rtTA) and tetracy-
cline-responsive element promoter (TRE).
We investigated these promoters in multiple cell lines derived
from several species to get a general sense of their behaviors. For
the mammalian promoters, we used mouse tail fibroblasts (129TF),
mouse embryonic fibroblasts (MEF), mouse myoblasts (C2C12),
rat mesenchymal stem cells (MSC), human fibroblasts (MRC5),
human fibrosarcoma cells (HT1080), human embryonic kidney
cells (293T), and rhesus macaque mammary tumor cells (CMMT).
For Drosophila promoters, we used two Drosophila melanogaster cell
lines, including the ML-DmBG3-c2 cell line (C2) derived from
larval central nervous system [8] and the S2R+ cell line (S2R+)
derived from late embryo [9,10].
Results and Discussion
For the six mammalian constitutive promoters, each one was
inserted into a lentiviral expressionv e c t o ri nfr o n to ft h eGF Pre p o r t e r
[11]. After the packaging of each vector into virus, cells were infected
by the virus at low titer such that only a small fraction of cells are
transduced. This ensures that the majority of transduced cells contain
one viral integration per cell. The lentiviral vector also carries
puromycin resistance, which was used to select for transduced cells.
We then quantitated GFP intensity by flow cytometry (Figure 1). It
showed that UBC is consistently the weakest promoter in all the cell
types while PGK is also consistently weak, though typically stronger
than UBC. By contrast, EF1A and CAGG promoters are consistent
strong in all the cell types, with EF1A being slightly stronger in some
cell types and slightly weaker in others. SV40 promoter is also fairly
strong, though generally somewhat weaker than EF1A and CAGG.
While there is cell type to cell type variability for all the promoters,
CMV promoter is the most variable, being very strong in some cell
types (e.g., 293T and CMMT) and rather weak in others (e.g.,M R C 5
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promoter in some cells as reported before [12,13,14].
We then examined COPIA and ACT5C promoters in the two
types of Drosophila cells. In our hands, lentiviral transduction killed
Drosophila cells. We therefore used conventional transient trans-
fection to deliver the vectors into the cells. We took care to use
identical transfection conditions so as to achieve comparable
transfection efficiencies between the COPIA-containing construct
and the ACT5C-containing construct. The two promoters
produced similar GFP signals in C2 and S2R+ cells, with ACT5C
being slightly stronger than COPIA (Figure 2).
To examine whether mammalian promoters could function in
fly cells, we also transfected the six mammalian promoters into
C2 and S2R+ cells. Surprisingly, with the exception of SV40, all
the mammalian promoters produced above-background levels of
GFP signals, with PGK producing a level of expression that
approaches that of COPIA and ACT5C (Figure 2). It is
interesting that PGK, which is a weak promoter in mammalian
cells, can behave as a fairly strong promoter in fly cells. It is also
interesting that mammalian promoters could be functionally
conserved, at least to some extent, in such evolutionary divergent
host cells.
One caveat of the flow cytometry measurement of GFP intensity
is that the stability of the GFP transcript and/or protein may differ
from cell type to cell type. As such, the comparison of GFP
intensity across cell types might not be a true reflection of
promoter strength in different cell types. However, the comparison
of GFP intensity from different promoters within a cell type should
reflect promoter strength.
We next examine the behavior of the rtTA-TRE inducible
system in the above mammalian and Drosophila cell types. In
addition to the TRE lentivirus, we also transduced mammalian
cells (or transfected Drosophila cells) with a vector carrying the rtTA
gene driven by the EF1A promoter. This vector also carries
neomycin resistance, which was used to select for transduced
mammalian cells. A range of doxycycline concentrations were
used to induce the TRE promoter, followed by flow cytometry
analysis of GFP intensity (Figure 3). At zero concentration of
doxycycline, GFP expression is essentially undetectable in all cell
types. At nonzero drug concentrations, different cell types
responded differently in terms of drug sensitivity and maximum
expression level. For example, CMMT cells turned on GFP at
much lower doxycycline concentrations as compared to C2C12
cells. GFP expression reached maximum for all cell types at about
110 ng/ml doxycycline concentration, though some cell types (e.g.,
MSC) reached plateau at a much lower doxycycline concentra-
tion. The maximum expression level from the TRE promoter in
any of the cell types is comparable to, or only slightly less than, a
strong constitutive promoter such as EF1A or CAGG in that cell
type (compare maximum TRE activities with that of other
promoters in Figures 1 and 2). Thus, the inducible rtTA-TRE
system can achieve high levels of gene expression while also
affording a means of tight regulation.
Materials and Methods
Plasmids containing promoters are obtained from the following
sources: EF1A, SV40, PGK, CAGG and UBC from published
sources [11,15,16], CMV from pEGFP-N1 vector of Clontech,
ACT5C from pUC-act-DHFR vector of Drosophila Genomics
Resources Center, COPIA from p8HCO of Drosophila Genomics
Resources Center [17], TRE from pBI-G vector of Clontech.
Sequences for these promoters are given in Supporting Informa-
tion, Text S1. Cells are obtained from the following sources:
C2C12, MRC5, MEF, HT1080 and CMMT from ATCC
(catalog: CRL-1772, CCL-171, TIB-81, CCL-121 and CRL-
Figure 1. Flow cytometry measurement of GFP fluorescence in eight mammalian cell types transduced with lentiviral vectors
carrying GFP reporter driven by promoters of interest. Six mammalian constitutive promoters were tested, along with the doxycycline-
inducible TRE promoter at maximal induction.
doi:10.1371/journal.pone.0010611.g001
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DmBG3-c2 and S2R+ from Drosophila Genomics Resources
Center (catalog: 62 and 150), and 129TF derived from a 129 strain
mouse in our lab.
Promoters are amplified by PCR using primers that contain
adaptor sequences to facilitate cloning into lentiviral vectors
containing puromycin resistance as previous described [11]. The
vectors are packaged into virus following previously described
Figure 3. Induction of TRE promoter driving GFP under different doses of doxycycline. Eight mammalian cell types and two Drosophila
cell types were used in the analysis. GFP fluorescence is quantitated by flow cytometry.
doi:10.1371/journal.pone.0010611.g003
Figure 2. Flow cytometry measurement of GFP fluorescence in two Drosophila cell types transduced with lentiviral vectors carrying
GFP reporter driven by promoters of interest. Two Drosophila constitutive promoters and six mammalian constitutive promoters were tested,
along with the doxycycline-inducible TRE promoter at maximal induction.
doi:10.1371/journal.pone.0010611.g002
Comparison of Promoters
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the stable integration of the lentiviral DNA into the host genome.
Transient transfection of Drosophila cells was carried out according
to published protocols [18].
Each batch of lentivirus was first tittered by infecting HT1080
cells with serial dilutions of the virus, followed by extended culture
under puromycin selection. Within some range of serial dilutions,
the vast majority of cells would be killed because they were not
infected, with a small number of infected cells growing up as visible
colonies after about 10 days. These colonies were counted and the
number was use to calculate viral titer. Once an accurate viral titer
was obtained, the virus was used to infect target cells at around 5%
infection rate. Infected cells were selected with puromycin two
days after infection for about 10 days before flow cytometry
analysis, which should kill all the uninfected cells based on drug
curves we had done on all the target cell types. To confirm that the
great majority of cells only had a single viral integration under the
above conditions, we co-infected cells with both GFP-bearing virus
and virus bearing the gene for red fluorescence protein (RFP) using
the same conditions. We observed that doubly infected cells (which
display both GFP and RFP) represented ,5% of total infected
cells. Drosophila cells were cultured for four days after transient
transfection before subjected to flow cytometry analysis.
For doxycycline induction of the TRE promoter, mammalian
cells are treated with doxycycline right after drgu selection while
Drosophila cells were treated one day after transient transfection.
Gene expression was induced within 12 hours and becomes stable
after another day of treatment.
Flow cytometry analysis was carried out on populations (as
opposed to clones) of cells. GFP fluorescence was measured on a
BD LSR II machine, with all the cells measured under the same
machine parameters. Each cell type and promoter combination
was done with three independent replicas, and each cytometric
measurement was done on 100,000 cells.
Supporting Information
Text S1 Promoter sequences.
Found at: doi:10.1371/journal.pone.0010611.s001 (0.03 MB
DOC)
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